update RLG Reports J&J/Ethicon Discontinuation of Four Surgical Mesh Products

Johnson & Johnson subsidiary Ethicon will stop selling four of its surgical mesh products: the Prolift, the Prolift+ M, TVT Secur, and Prosima systems.
Ethicon announced its plans to stop selling these four products in a letter to U.S. District Judge Joseph R. Goodwin that the company filed yesterday in the U.S. District Court for the Southern District of West Virginia, where Judge Goodwin is presiding over the pre-trial proceedings of a multi-district litigation (MDL No. 2327) consolidating hundreds of cases against Ethicon for surgical mesh injuries. The letter reportedly states that “Ethicon has asked the FDA for 120 days to end sales so it can ‘notify its customers and provide those hospitals and surgeons with sufficient time to select alternative treatment options for their patients. The letter reportedly also stated that “Ethicon will also discontinue or revise, as appropriate, all marketing materials during this time.”
According to a June 5, 2012, Bloomberg News article, Ethicon also said that it has asked the FDA to let the company continue selling a fifth product, the Gyencare Gynemesh, with a change to the product’s labeling that would limit Gynemesh’s use to repair surgeries that implant mesh through a woman’s abdomen, as opposed to through a woman’s vagina (i.e., transvaginally). In announcements questioning the safety of using surgical mesh to treat a common female condition known as pelvic organ prolapse (POP), the FDA has singled out transvaginal repair as being particularly problematic.
As a law firm that is representing many of the claimants in the surgical mesh MDLs against Ethicon and other mesh manufacturers, the Rottenstein Law Group is encouraged by Ethicon’s voluntary recall of four of its surgical mesh products that have been used for the transvaginal repair of POP.

Join the Discussion

Please note: Comments are encouraged in order to permit visitors to discuss relevant topics. Comments are moderated and might be edited by RLG before being published.

Comments should not be used to ask questions of RLG’s lawyers; if you want to speak with a lawyer, please fill out this contact form or call 1 (888) 976-8529. *Your name and email address will not be published.

*

  


eight − = 3

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

RLG encourages you to reproduce our original content—on your own web site; in emails to your friends and family; in blogs, posts, and tweets, etc.—but we ask that you please attribute whatever you use to us, and, whenever possible, provide a link to the page where you first found the material. That way, whoever reads your excerpt might read more informative material of interest at one of RLG's sites.
You’ve taken enough. We'll take it from here. Click here to contact us now.